Kornimate/medical-research-clean huggingface dataset:
sensory phenotypes of autism spectrum disorder

Conditions: Autism

Summary: this project plans to establish sensory phenotypes of a taiwanese asd cohort across lifespan, including variety of sensory modalities, sensory domains, and clinical correlates. also, we will clarify the relationship between sensory phenotypes and social impairment by two specific sensory-social paradigms targeting eye gaze avoidance and social touch anxiety, as well as the atypical neural representation of asd during eye gaze and viewing social touch by fmri and eeg.

sensory disturbance of autism spectrum disorder (asd) are life-long highly-impairing challenges for the individual. anxiety and fear around the sensory issues significantly threatens the psychological and mental health. as a newly introduced diagnostic criteria of asd, sensory characteristics becomes a recent focus of asd research. the asd population is aging, how their sensory features naturally change with age is particular relevant for their adaptation. however, current literature are limited to childhood and young adults and mostly rely on behavioral report, lacking a clear whole picture of changing sensory phenotype in terms of different sensory modality and sensory domains. besides, how sensory characteristics in asd can be quantified by objective measures or explored by qualitative approach, how the sensory sensitivity contributes to the core social deficits in asd such as eye gaze or social touch avoidance are unclear. this project plans to achieve the following aims: 1. establish sensory phenotypes of a taiwanese asd cohort across lifespan, including variety of sensory modalities (i.e., visual, tactile, auditory, smell/taste, proprioception, etc.), sensory domains (i.e., low registration, sensory seeking, sensory sensitivity, and sensory avoiding), and clinical correlates. 2. clarify the relationship between sensory phenotypes and social impairment by two specific sensory-social paradigms targeting eye gaze avoidance and social touch anxiety, which are hallmarks of asd. factors of emotion types as well as familiarity of faces or social/object touch will be manipulated to examine how they moderate eye tracking and pupil response. 3. identify the atypical neural representation of asd during eye gaze and viewing social touch by fmri and eeg.

Eligibility criteria:
aim#1 inclusion criteria: * diagnosis of autism spectrum disorder aim#2 and #3 asd group: inclusion criteria: * diagnosis of autism spectrum disorder * age above 12-40 years old exclusion criteria: * no diagnosis of autism spectrum disorder * pregnant woman * metal implant in the body td group: inclusion criteria: * no diagnosis of autism spectrum disorder * age above 12-40 years old exclusion criteria: * history of major psychiatric disorders * pregnant woman * metal implant in the body
time to excretion of contrast, a maastricht prospective observational study

Conditions: Renal Insufficiency; Acute Kidney Injury; Contrast-induced Nephropathy

Summary: risk of contrast-induced kidney injury is expected to be strongly correlated with exposure time. studies on the excretion of iodinated contrast material are few and have mostly been carried out in patients with normal renal function. although case wise reports of persistent renograms have been published, it is not known how long contrast is retained before excretion in patients with egfr \ =60 ml/min/1.73m2.

the primary aim of the current study is to determine contrast elimination time and % in three groups of patients, (with severely reduced, moderate, and mildly reduced to normal renal function). secondary aims are to explore whether specific situations/characteristics result in higher probability of delayed elimination of contrast, and whether there is a link between elimination time and adverse post-contrast outcomes (post-contrast incidences of acute kidney injury; post-contrast changes in egfr within 5 days from baseline; 1-month post-contrast change in egfr; 1-month post-contrast incidences of egfr decline \>=5 ml/min/1.73m2; 1-month dialysis and mortality).

Eligibility criteria:
inclusion criteria: - egfr \<30 ml/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at maastricht umc+ for each included patient with egfr \<30 ml/min/1.73m2, two matched patients will be included: * 1. egfr 30-59 ml/min/1.73m2 referred for an elective procedure with intravascular administration of iodinated contrast material at maastricht umc+ with age, sex and contrast procedure type matching the age, sex and contrast procedure type of an egfr \<30 ml/min/1.73m2 participant. * 2. egfr \>=60 ml/min/1.73m2 referred for an elective procedure with intravascular administration of iodinated contrast material at maastricht umc+ with age, sex and contrast procedure type matching the age, sex and contrast procedure type of an egfr \<30 ml/min/1.73m2 participant. exclusion criteria: * age \<18 years * dialysis or pre-dialysis * intravascular contrast administration having occurred \<30 days before the first baseline sample * emergency or intensive care status.

Keywords: intravascular iodinated contrast contrast-induced acute kidney injury post-contrast acute kidney injury iodinated contrast elimination time contrast retention delayed contrast elimination
multicenter, prospective, non-interventional, observational study to confirm the long-term efficacy and safety of rosuampin tab. in patients with hypertension and hypercholesterolemia

Conditions: Hypertension; Hypercholesterolemia

Summary: this study is to confirm the long-term efficacy and safety of rosuampin tab. in patients with hypertension and hypercholesterolemia

all treatments, such as drug administration and clinical laboratory tests performed after rosuampine administration, are performed according to the investigator's medical judgment, and information to be confirmed in this observational study is collected for up to 12 months.

Eligibility criteria:
inclusion criteria: 1. aged ≥ 19 years 2. patients with hypertension and hypercholesterolemia who are receiving rosuampin medication or need rosuampin medication according to the medical judgment of the investigator 3. written informed consent exclusion criteria: 1. patients with hypersensitivity to components of this drug or other dihydropyridine drugs 2. a woman who is pregnant or likely to be pregnant, a woman of childbearing age who does not use appropriate contraception and a nursing woman 3. a patient with severe liver failure 4. patients with active liver disease who include continuous serum transaminase elevation of unknown cause or serum transaminase elevation over three times the upper limit of normal 5. a patient with severe aortic valvular stenosis 6. a myopathy patient 7. a cyclosporine co-administered patient 8. a patient with severe renal failure (clcr, creatinine clearance \<30 ml/min)

Keywords: long-term efficacy and safety of rusuampin tab
efficacy, safety, and tolerability of aclidinium bromide in the treatment of moderate-to-severe chronic obstructive pulmonary disease (copd) (las-md-38)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease. the study will be 56 weeks in duration; a 2-week run-in period followed by a 12-week double-blind, placebo-controlled treatment period. this will be followed by an open-label 40-week treatment period and a 2-week follow up phone call. all patients will receive the higher aclidinium bromide during the 40-week open label treatment period.


Eligibility criteria:
inclusion criteria: * a diagnosis of stable moderate to severe copd as defined by the global initiative for chronic obstructive lung disease (gold) guidelines, 2008; postbronchodilator fev1/fvc \< 70%, and postbronchodilator fev1 ≥ 30% and \< 80% predicted * current or former cigarette smokers exclusion criteria: * patients who have been hospitalized for an acute copd exacerbation within 3 months before the first visit * respiratory tract infection or copd exacerbation in the 6 weeks before visit 1 * patient with any clinically significant respiratory conditions other than copd, cardiovascular conditions or mental illness * history or presence of asthma verified from medical records * chronic use of oxygen therapy greater than or equal to 15 hours per day * patient with uncontrolled infection due to hiv and/or active hepatitis * patients with a history of hypersensitivity reaction to inhaled anticholinergics * patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.

Keywords: chronic obstructive pulmonary disease copd chronic bronchitis emphysema airflow obstruction, chronic chronic airflow obstruction chronic obstructive airway disease chronic obstructive lung disease
social media listening in improving clinical trial recruitment in patients with cancer

Conditions: Breast Carcinoma; Colon Carcinoma; Kidney Carcinoma; Lymphoma; Non-Small Cell Lung Carcinoma; Prostate Carcinoma

Summary: this pilot clinical trial studies how well social media listening works in improving clinical trial recruitment in patients with cancer. social media listening and recruitment on twitter may enhance enrollment for cancer-related clinical trials.

primary objectives: i. examine the feasibility (acceptance among university of southern california \[usc\] norris study team members and twitter users in los angeles \[la\] county) of targeted social media listening (sml) via twitter as a tool for enhancing recruitment to cancer trials. ii. gain preliminary data on the impact (i.e., numbers recruited versus projected accrual compared to historic recruitment) of targeted social media listening (sml) as a tool for enhancing recruitment to cancer trials among twitter users in la county. iii. estimate the effect size of the number of people enrolled associated with the use of targeted social media listening (sml) via twitter as a tool for enhancing recruitment to cancer trials. outline: patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via twitter. patients are then contacted for recruitment into a clinical trial.

Eligibility criteria:
inclusion criteria: * trial inclusion: * focus on one of the following disease categories: non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma * be a phase 1 trial in expansion, phase 2, or 3 * be interventional trials * recruit in english * be institutional review board (irb)-approved and open to accrual at usc norris * recruit for at least 9 months at the point of enrollment * set monthly accrual target \>= 1/ and annual accrual target \>= 12 * patient inclusion: * will include all prospective trial participants in this study that come from twitter in response of our sm recruitment interventions, provided they meet the specific trial's eligibility criteria exclusion criteria: * trial exclusion: * phase 1 trials in dose escalation * patient exclusion: * persons who do not meet the eligibility criteria of any of the trials open to accrual will be excluded from participation, and persons who may be eligible (e.g., disease/histology, stage, prior treatment) but do not meet additional trial-specific requirements such as insurance or allergy to drug)
effectiveness of a lightweight mesh in the laparoscopic prevention of parastomal hernia

Conditions: Parastomal Hernia

Summary: the purpose of this study is to determine if a mesh is effective in the prevention of a parastomal hernia when a permanent ostomy is performed through a laparoscopic approach.

parastomal hernia (ph) is a very common complication after abdominal surgery that requires a permanent ostomy. this type of surgery is usually associated with processes that fall within the scope of coloproctology.ph is difficult to deal with high rates of recurrence after surgical repair.this type of hernia remains a problem of first order, generating a significant consumption of health and economic resources and determining an impaired quality of life of these patients.laparoscopic surgery is increasingly used in colorectal surgery. also with this type of approach is present the problem of prevention of ph. the use of a mesh in the repair of hernias is not discussed since the placement of a prosthesis significantly reduces the recurrence rate. there are now many types of prosthetic meshes available. a low weight mesh composed of large pores (about 5mm) with a high proportion of absorbable material and a layer of oxidized regenerated cellulose which is placed in the vicinity of the bowel is available on the market (proceed ®, ethicon). the introduction of this low-weight mesh provides a good opportunity to prevent the development of an ph when we use a laparoscopic approach.

Eligibility criteria:
inclusion criteria: * patients with permanent ostomy and 1 years of life expectancy * signed informed consent exclusion criteria: * allergy to the compounds of the mesh * rejection of the patient * rejection of the surgeon * field of emergency * life expectancy \< 1 year * prior meshes in the surgical site

Keywords: parastomal, hernia
effects of sglt2i on the cognitive function in t2dm patient (escdp)

Conditions: Diabetes Mellitus, Type 2; Cognitive Functions Confusion

Summary: type 2 diabetes is associated with diabetic cognopathy, the prevalence of alzheimer's disease(ad) in t2dm patients is 1.5 to 2.5 times higher than the general population. cognitive impairment seriously affects the health and quality of life of the elderly. prevention and treatment measures for cognitive decline in persons with t2dm has not been well studied. sodium-glucose transporter-2 (sglt-2) inhibitors, which lower serum glucose by inhibiting sglt2-mediated glucose reabsorption in renal proximal tubules, could be neuroprotective. it was recently reported that the sglt-2 inhibitor improved cognitive function and ameliorated oxidative stress via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in mice or hfd-induced obese rats, that means sglt-2 inhibitor may provide neuroprotection in the diabetic brain. hence, invokana (canagliflozin) might act as a potent dual inhibitor of ache and sglt2. since the development of diabetes is associated with ad, the design of new ache inhibitors based on antidiabetic drug scaffolds would be particularly beneficial. moreover, the present computational study reveals that invokana (canagliflozin) is expected to form the basis of a future dual therapy against diabetes associated neurological disorders. the overall goal of this study is to explore the effects of sglt2 inhibitor on the cognitive function in patients with type 2 diabetes mellitus and make further contribution to the improvement of cognitive function.


Eligibility criteria:
inclusion criteria: * newly onset type 2 diabetes within 3 months * 7%\<hba1c\<10% exclusion criteria: * type 2 diabetes with acute diabetic complications. * type1 diabetes. * thyroid dysfuncition. * any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs. * history of cardio-cerebral vascular events, such as congestive heart failure, myocardial infarction or stroke within 3 months. * hepatic insufficiency (ast or ast is twice higher than the upper limit) or history of hepatitis or cirrhosis, hepatic encephalopathy. * renal insufficiency (serum creatinine 1.5 times higher than the upper limit) or history of dialysis and nephritic syndrome. * acute infections, tumor, severe arrhythmia. * alcohol or medicine addiction, psychoactive substance abuse. * other diseases affecting cognitive function (congenital dementia, brain trauma, parkinson's diseases, toxicencephacopathy,epilepsy, mental disorders, severe lungdy sfunction, epilepsy, severe hypoglycemic coma, cerebrovascular disease, ischemic heart disease, etc.) * fertile woman without contraceptives. * allergic to or have contraindication to the intervention drugs.

Keywords: diabetes mellitus cognitive functions sodium glucose transporter
an investigational scan (dual energy ct) in detecting gastrointestinal carcinoid tumors

Conditions: Carcinoid Syndrome; Carcinoid Tumor; Digestive System Neuroendocrine Tumor G1; Metastatic Carcinoid Tumor

Summary: this trial studies the use of a special type of computed (ct) scan called dual energy ct in detecting gastrointestinal carcinoid tumors. ct is an imaging technique that uses x-rays and a computer to create images of areas inside the body. dual energy computed tomography is a technique used during routine ct scans to help obtain and process the image after the scan is complete. doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine ct scans.

primary objectives: i. evaluate prospectively the sensitivity and specificity of dual energy computed tomography (ct) in detecting primary gastrointestinal (gi) carcinoid. outline: patients undergo one dual energy ct scan during scheduled ct scan.

Eligibility criteria:
inclusion criteria: * patients with: clinical features of carcinoid syndrome (or) increased serum and urinary markers suggestive of carcinoid (or) endoscopic biopsy proven carcinoid (or) metastases which are biopsy proven as carcinoid. * patient is scheduled to have a clinically indicated staging ct exam. * patients who have signed their informed consent form to undergo the study. exclusion criteria: * patients who have already had their primary gi carcinoid resected. * contraindication to intravenous contrast agents (e.g. allergy, renal failure, dialysis, pregnancy etc.). * pregnant patients.
ranibizumab intravitreal injections in patients with visual impairment due to macular edema secondary to central retinal vein occlusion

Conditions: Macular Edema; Central Retinal Vein Occlusion

Summary: the present study provided additional efficacy and safety data for 0.5-mg ranibizumab using as needed (prn) dosing over 24 months in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (crvo). spectral domain high-definition optical coherence tomography (oct) images was analyzed to gain insights into predictive factors for disease progression and the possibility of reduced monitoring was assessed in year 2. the results of this open-label study provided long-term safety and efficacy data to further guide recommendations on the use of ranibizumab in this indication.


Eligibility criteria:
inclusion criteria: * male or female patients ≥ 18 years of age * diagnosis of visual impairment exclusively due to me secondary to crvo * bcva score at screening and baseline between 73 and 19 letters early treatment diabetic retinopathy study (etdrs), inclusively (approximate snellen chart equivalent of 20/40 and 20/400) exclusion criteria: * uncontrolled blood pressure defined as systolic value of \> 160 mm hg or diastolic value of \> 100 mm hg at screening or baseline. * any active periocular or ocular infection or inflammation at screening or baseline in either eye * uncontrolled glaucoma at screening or baseline or diagnosed within 6 months before baseline in either eye * use of any systemic antivascular endothelial growth factor (anti-vegf) drugs within 6 months before baseline (eg, sorafenib \[nexavar®\], sunitinib \[sutent®\], bevacizumab \[avastin®\])

Keywords: ophthalmology ranibizumab central retinal vein occlusion
a first in human study of tt5 in single and multiple ascending doses in healthy volunteers and surgical patients

Conditions: Pain

Summary: this study is a first in human, three-parts, double-blind, randomized, placebo-controlled, single and multiple ascending dose study. the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of tt5 at different doses in healthy and surgical participants.

the study will be divided into three parts: part a: single ascending dose - healthy participants cohorts with up to 5 dose levels. part b: multiple ascending doses - healthy participants cohorts with up to 3 dose levels. part c: surgical patients cohorts with up to 3 dose levels. the primary objective is to investigate the safety and tolerability of tt5 in single and multiple ascending intravenous doses in healthy participants and in surgical patients. the secondary objectives are to investigate the pharmacokinetics (pk) of tt5 after single and multiple ascending intravenous doses in healthy participants and after intravenous doses in surgical patients. * to investigate the acute and chronic psychological subjective response of the healthy participants and surgical patients to tt5 * to assess the pharmacodynamics (pd) of tt5 after intravenous doses in surgical patients. exploratory objectives areto explore potential fluid biomarkers for tt5

Eligibility criteria:
main inclusion criteria for parts a and b: * non-smoker for the confinement period of the study. * medically healthy and without clinically significant abnormalities. * negative screen for alcohol and drugs of abuse. * no history of psychiatric disorders. * female participants of non-childbearing potential must be post-menopausal or surgically sterile at least 3 months prior to dosing. * sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study. * able to understand the study procedures and provide signed informed consent to participate in the study in english. main exclusion criteria for parts a and b: * history of clinically significant asthma, anaphylaxis, major medical, psychiatric illness or surgery. * acute or chronic clinically relevant systemic disease or disorder. * renal insufficiency * history of drug or alcohol consumption abuse. * drinking excessive amounts of tea, coffee, chocolate and/or beverage containing caffeine. * have used any investigational drug or participated in any clinical trial within 4 weeks prior to screening. * unable to refrain from strenuous exercise. * participant who has received blood or plasma derivatives, who had a surgery or who has given blood within 4 weeks prior to the screening visit or has planned to give blood or sperm within the 90 days following the study. * pregnant or lactating female participant.